Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Targeted Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma

NCT06715072 is registered in ClinicalTrials.gov with Yao Xie as lead sponsor.

NCT NCT06715072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06715072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Targeted Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma
Lead sponsor
Yao Xie
Phase
Observational
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
December 31, 2026
Enrollment
70 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable liver cancer